What is the appropriate treatment approach for an acute Crohn disease flare?

Treatment of Acute Crohn's Disease Flare

For moderate-to-severe Crohn's disease flares, initiate oral prednisone 40-60 mg daily and evaluate response at 2-4 weeks; patients with high-risk features (stricturing/penetrating disease, perianal fistulas, age <40, or steroid requirement at diagnosis) should receive anti-TNF biologics as first-line therapy instead. 1, 2

Disease Severity Assessment Before Treatment

Before selecting therapy, you must stratify disease severity and identify high-risk features that mandate early biologic use rather than steroids: 1, 2

• High-risk features: stricturing or penetrating disease, perianal fistulas, age <40 years at diagnosis, need for steroids at presentation 1, 2
• Disease location: ileal/ileocolonic vs colonic involvement determines specific drug selection 1
• Inflammatory markers: elevated CRP and fecal calprotectin confirm active inflammation 1, 2

Treatment Algorithm by Disease Severity

Mild-to-Moderate Ileal or Right Colonic Disease

Oral budesonide 9 mg daily is first-line therapy for localized ileocecal disease, providing topical anti-inflammatory effect with minimal systemic absorption and fewer side effects than prednisone. 1, 2

• Reassess clinical response at 4-8 weeks 2
• If inadequate response, escalate to prednisone 40-60 mg daily 2, 3
• Never use budesonide for maintenance—it does not sustain remission 2

Mild Colonic Disease (Colon-Limited)

Sulfasalazine 4-6 g daily is the only effective 5-ASA agent for Crohn's colitis; other mesalamine formulations are ineffective and should be avoided. 1, 2

• Evaluate response at 2-4 months 2
• Other 5-ASA compounds have no role in Crohn's disease 1, 2

Moderate-to-Severe Disease WITHOUT High-Risk Features

Oral prednisone 40-60 mg daily induces remission in 60-83% of patients and is approximately twice as effective as placebo (RR 1.99,95% CI 1.51-2.64). 1, 2, 3

• Assess response at 2-4 weeks 1, 2
• If remission achieved, taper gradually over 8 weeks—rapid tapering causes early relapse 1, 2
• Corticosteroids must never be used for maintenance due to complete lack of efficacy and significant toxicity 1, 2

For patients responding to prednisone, consider adding thiopurine (azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day) or parenteral methotrexate as steroid-sparing maintenance therapy, evaluating at 12-16 weeks. 1, 2

Moderate-to-Severe Disease WITH High-Risk Features

Anti-TNF biologics (infliximab or adalimumab) should be initiated immediately as first-line therapy rather than steroids, as early effective treatment prevents complications, hospitalizations, and disability. 1, 2

• Evaluate response at 8-12 weeks 2
• Combination therapy with thiopurine or methotrexate reduces immunogenicity and improves remission rates, though infection risk increases (particularly in older adults and young males) 1, 2
• Alternative first-line biologics include vedolizumab, ustekinumab, or guselkumab 1, 2
• Continue the same biologic indefinitely for maintenance if response achieved 1, 2

The 2025 British Society of Gastroenterology guidelines and 2024 ECCO guidelines now support "top-down" approaches with early advanced therapies, as three large prospective studies (including PROFILE) demonstrated superiority in efficacy, safety, endoscopic remission, and reduced surgery/hospitalization compared to "step-up" strategies. 1

Severe Disease Requiring Hospitalization

Intravenous methylprednisolone 40-60 mg daily (typically 40 mg every 8 hours) is initial therapy for hospitalized patients. 1, 2

• Assess symptomatic response within 1 week 1, 2
• Lack of response mandates escalation to biologic therapy or surgical consultation 1, 2
• Provide supportive care: IV fluids, electrolyte replacement (≥60 mmol/day potassium), low-molecular-weight heparin for thromboprophylaxis 1
• Consider concomitant IV metronidazole if septic complications cannot be excluded 1

Therapies to Avoid

The following have no role in treating Crohn's flares: 1, 2

• Mesalamine/5-ASA (except sulfasalazine for colonic disease)—ineffective for Crohn's disease 1, 2
• Thiopurine monotherapy for induction—too slow (RR 1.23 vs placebo, 95% CI 0.97-1.55) 2
• Probiotics, omega-3 fatty acids, marijuana, naltrexone—no evidence for efficacy 2
• Systemic antibiotics (except for documented sepsis/abscess)—insufficient evidence 1, 2

Critical Pitfalls to Avoid

• Using corticosteroids for maintenance—completely ineffective and causes toxicity (osteoporosis, infection, metabolic complications) 1, 2
• Delaying biologics in high-risk patients—leads to irreversible complications and disability 1, 2
• Rapid steroid tapering—associated with early relapse; taper over 8 weeks 1, 2
• Continuing ineffective therapy beyond evaluation timepoints—reassess at specified intervals and modify promptly 1, 2
• Prescribing 5-ASA agents other than sulfasalazine—no benefit in Crohn's disease 1, 2

Special Considerations

Exclusive enteral nutrition (EEN) can be used as an alternative to steroids in motivated adults with mild-to-moderate disease who have dietetic support and prefer to avoid corticosteroids, though compliance is challenging. 1

Surgery should be considered for patients failing medical therapy and may be appropriate as primary therapy for limited ileal or ileocecal disease. 1

For perianal fistulizing disease, first-line treatment is metronidazole 400 mg three times daily and/or ciprofloxacin 500 mg twice daily, with infliximab reserved for refractory cases as part of a combined medical-surgical strategy. 1